Cambridge Healthtech Institute’s 5th Annual

Immuno-Oncology Biomarkers

Predictive Biomarkers and Companion Diagnostics

August 10-11, 2020



As pharmaceutical and biotechnology companies increase their investment in immuno-oncology programs to facilitate rapid development of novel immunotherapies, there is increasing pressure to discover and validate relevant biomarkers. Cambridge Healthtech Institute’s Fifth Annual Immuno-Oncology Biomarkers meeting will bring together biomarkers experts from industry and academia to address rapid development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics.

Preliminary Agenda

BIOMARKERS AND COMPANION DIAGNOSTICS TO PREDICT RESPONSE TO IMMUNOTHERAPY

Immunotherapy Biomarkers – Blood and Tumor State of the Art

Adil Daud, MD, Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Prediction of Benefit from Immunotherapy: PD-L1 and Beyond

David L. Rimm, MD, PhD, Professor, Pathology and Medicine (Oncology); Director, Translational Pathology, Yale University School of Medicine

PD-L1 as a Companion Diagnostic for Tumors beyond Non-Small Cell Lung Cancer: It’s the Same Thing, Only Different

Kenneth Emancipator, MD, Executive Medical Director, Companion Diagnostics and Translational Medicine, Merck & Co., Inc.

Exosomes and Their Role as Biomarkers in Cancer

Theresa Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, Hillman Cancer Center, University of Pittsburgh School of Medicine

Guiding the Personalization of Immunotherapy in Cancer through Biology and Biomarkers – Predicting Response and Toxicity

Justin M. Balko, PharmD, PhD, Associate Professor, Departments of Medicine and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center

GENOMIC BIOMARKERS AND IMMUNE MONITORING FOR IMMUNOTHERAPY DEVELOPMENT

The Influence of the Cancer Genome on Tumor Immunity

Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center

Multiparametric Immune Monitoring of Multi-Center I/O Clinical Trials: Uncovering Hidden Correlates of Response

Steven P. Fling, PhD, Senior Staff Scientist, Vaccine and Infectious Disease Division; Director, CITN/ION Central Immune Monitoring Lab, Fred Hutchinson Cancer Research Center

Talk Title to be Announced

Genevieve Boland, MD, PhD, Assistant Professor, Surgery; Director, Melanoma Surgery Program, Massachusetts General Hospital

Replication Stress Response Defects Predict Response to Immune Checkpoint Blockade in Non-Hypermutated Cancers

Shiaw-Yih (Phoebus) Lin, PhD, Professor, Systems Biology, MD Anderson Cancer Center

TUMOR IMMUNE MICROENVIRONMENT CHARACTERIZATION

Talk Title to be Announced

Shahram Salek-Ardakani, PhD, Director, Cancer Immunology, Pfizer

Hedgehog Signaling and the Impact on Tumor Response to PD-1 Targeted Therapies

Yiping Yang, MD, Director, Division of Hematology, Internal Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and The Ohio State University College of Medicine

Profiling the Tumor Microenvironment for Immunotherapy Targets

Donald R. Shaffer, PhD, Director, Head of Discovery, Jounce Therapeutics




For more details on the conference, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com


Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com